Abstract
Background. A significant place among pediatric urination disorders is occupied by overactive bladder (OAB). Treatment involving the use of M-anticholinergics is aimed to suppress detrusor overactivity. The side effects of treatment include urination problems, incomplete bladder emptying (residual urine), and acute urinary retention. Methods. We monitored 20 children aged 5–15 years, among them 12 boys and 8 girls. The average age (М±δ) was 8.47 ± 3.46 years. The 2-day uroflow monitoring revealed residual urine (RU) in 9 patients (1–15 times per monitoring period). The urination volume and rate, as well as RU, were assessed by uroflow monitoring conducted at home using the SIGMA F uroflowmeter (RZN registration certificate No. 2020/11522 of 5.08.2020). One of the components of combination therapy was trospium chloride (Spasmex) in a dose of 10–15 mg per day, depending on the age and disorder. Statistical data processing was performed using the STATISTICA 10 (StatSoft, Inc., USA) and Excel (Microsoft Office 2016) software packages. The differences were considered significant at p<0.05. The descriptive statistics were presented as М±δ (where М was median, δ was standard deviation).
Results. The average effective volume (AEV) of urination in the group was reduced by 10–86.5% relative to the age norm. Furthermore, incomplete bladder emptying was reported in 9 patients. After treatment, the minimum urine output volume and the maximum urine flow rate increased significantly, while the urination rate decreased. There were no significant changes in the urine output volume (average and maximum), however, an upward trend of the urine output volume was observed. No increase in the number of RU cases following prescription of trospium chloride was reported. In fact, the decrease in their number was recorded. Conclusion. Pediatric micturition cycle abnormalities also include the RU symptom. The M-anticholinergic drug, trospium chloride (Spasmex), in a daily dose of 10-15 mg represents a safe and effective medication option. Therapy lasting up to 2 months results in the significant increase in minimum bladder volume and maximum urine flow rate, the decrease in pollakiuria severity, but never changes the rate and amount of residual urine.
Keywords: urination disorders, children, uroflowmetry, uroflow monitoring, trospium chloride, residual urine.
For citation:Danilov V.V., Golovina O.B., Danilov V.V. Trospium chloride in children: dynamic changes of the residual urine symptom during treatment of urination disorders. Clinical review for general practice. 2024; 5 (3): 99–104. DOI: 10.47407/kr2023.5.3.00367
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
